Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
RegenXBio ( (RGNX) ) has issued an announcement.
On January 14, 2025, REGENXBIO Inc. announced a strategic collaboration with Nippon Shinyaku Co., Ltd. to develop and commercialize RGX-121 and RGX-111, aimed at treating Mucopolysaccharidosis II and I respectively. The agreement involves REGENXBIO receiving an upfront payment of $110 million and potential milestone payments totaling up to $700 million, along with significant royalties. REGENXBIO will lead the manufacturing of these gene therapies, while Nippon Shinyaku will handle their commercialization in the U.S. and Asia. This partnership is expected to enhance both companies’ positions in the gene therapy market, offering potentially transformative treatments for these rare diseases.
More about RegenXBio
REGENXBIO Inc. is a leading clinical-stage biotechnology company that focuses on developing gene therapies. The company is known for its AAV Therapeutics platform, which aims to provide innovative treatments for retinal and rare diseases, including MPS II and MPS I. Established in 2009, REGENXBIO has been at the forefront of advancing gene therapy medicines with the potential to revolutionize healthcare.
YTD Price Performance: -11.58%
Average Trading Volume: 1,176,333
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $372.1M
See more data about RGNX stock on TipRanks’ Stock Analysis page.
